A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy.
Details
Serval ID
serval:BIB_F0DE70262735
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy.
Journal
Blood purification
ISSN
1421-9735 (Electronic)
ISSN-L
0253-5068
Publication state
Published
Issued date
2017
Peer-reviewed
Oui
Volume
43
Number
1-3
Pages
11-17
Language
english
Notes
Publication types: Evaluation Studies ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Omni® (B. Braun, Germany) is a new-generation, continuous renal replacement therapy (CRRT) machine designed to improve user interface, minimize downtime and optimize renal dose delivery. It was never tested in humans.
We used Omni® to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey.
CRRT was delivered using Omni® in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent.
CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni® in a safe and efficient way for 10 critically ill patients. Video Journal Club 'Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.
We used Omni® to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey.
CRRT was delivered using Omni® in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent.
CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni® in a safe and efficient way for 10 critically ill patients. Video Journal Club 'Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.
Keywords
Citric Acid/therapeutic use, Critical Illness, Equipment Design, Heparin/therapeutic use, Humans, Patient Safety, Renal Replacement Therapy/instrumentation, Time Factors
Pubmed
Web of science
Open Access
Yes
Create date
05/12/2016 19:06
Last modification date
20/08/2019 17:18
Usage data
